Hematologic and cytogenetic data obtained during the clinical course of the patient with t(4;12)(p16;p13)
Date . | October 2000 . | December 2000 . | September 2000 . | December 2001 . | February 2002 . | June 2002 . | January 2003 . |
|---|---|---|---|---|---|---|---|
| Clinical diagnosis | NHL PTCL stage IVb | NHL in CR | AML M0 | AML in CR | AML in CR | AML M0 with fibrosis | AML M0 with fibrosis |
| Disease status | PTCL onset | CR | AML onset | CR | CR | AML relapse | NR |
| WBC count, × 103/μL | 5.74 | 1.61 | 15.24 | 3.50 | 2.15 | 1.64 | 0.89 |
| Neutrophils, % | 57.0 | 21.0 | 32.0 | 60.0 | 45.0 | 36.0 | 20.0 |
| Monocytes, % | 8.0 | 23.0 | 16.0 | 16.0 | 18.0 | 13.0 | 3.0 |
| Eosinophils, % | 7.0 | 2.0 | 1.0 | 0.0 | 1.0 | 2.0 | 0.0 |
| Blasts, % | 0.0 | 0.0 | 39.0 | + | + | 3.0 | 70.0 |
| BM aspirate blasts, % | 2.8 | 2.7 | 43.8 | 0.5 | 1.2 | 16.5 | ND |
| Karyotype* | 46,XX, t(4;12) (p16;p13)[3] 49,XX, +i(1)(q10),t(4;12) (p16;p13), +10, +19[10] 49,XX, +i(1)(q10), +11, +19[3] 46,XX[4] | 46,XX, t(4;12) (p16;p13)[2] 46,XX,inv(3) (q21;q26)[1] 46,XX[17] | 46,XX,t(3;8)(q27;q24),t(4;12) (p16;p13)[20] | 46,XX,t(4;12) (p16;p13)[2] 46,XX[18] | 46,XX,t(4;12) (p16;p13), inc[1]46,XX[39] | 46,XX,t(4;12)(p16;p13) [2]46,XX, t(3;8)(q27;q24), t(4;12)(p16;p13)[1] | 46,XX, t(2;2)(p21;p25), t(3;8)(q27;q24), t(4;12)(p16;p13) add(7)(q22) [20] |
| Chemotherapy | THP-COP(THP+CPA+VCR+PSL) | THP-COP (THP+CPA+VCR+PSL) | IDA+Ara-C MIT+Ara-C | DNR+Ara-C c+PSL ACR+Ara-C c+PSL | Ara-C+VP-16+PSL,VCR,VDS | Ara-C+VP-16+PSL,VCR,VDS | Palliative therapy |
| RT-PCR for TEL-FGFR3 | +, BM | +, BM | +, BM; +, PB | ND | ND | ND | +, PB |
Date . | October 2000 . | December 2000 . | September 2000 . | December 2001 . | February 2002 . | June 2002 . | January 2003 . |
|---|---|---|---|---|---|---|---|
| Clinical diagnosis | NHL PTCL stage IVb | NHL in CR | AML M0 | AML in CR | AML in CR | AML M0 with fibrosis | AML M0 with fibrosis |
| Disease status | PTCL onset | CR | AML onset | CR | CR | AML relapse | NR |
| WBC count, × 103/μL | 5.74 | 1.61 | 15.24 | 3.50 | 2.15 | 1.64 | 0.89 |
| Neutrophils, % | 57.0 | 21.0 | 32.0 | 60.0 | 45.0 | 36.0 | 20.0 |
| Monocytes, % | 8.0 | 23.0 | 16.0 | 16.0 | 18.0 | 13.0 | 3.0 |
| Eosinophils, % | 7.0 | 2.0 | 1.0 | 0.0 | 1.0 | 2.0 | 0.0 |
| Blasts, % | 0.0 | 0.0 | 39.0 | + | + | 3.0 | 70.0 |
| BM aspirate blasts, % | 2.8 | 2.7 | 43.8 | 0.5 | 1.2 | 16.5 | ND |
| Karyotype* | 46,XX, t(4;12) (p16;p13)[3] 49,XX, +i(1)(q10),t(4;12) (p16;p13), +10, +19[10] 49,XX, +i(1)(q10), +11, +19[3] 46,XX[4] | 46,XX, t(4;12) (p16;p13)[2] 46,XX,inv(3) (q21;q26)[1] 46,XX[17] | 46,XX,t(3;8)(q27;q24),t(4;12) (p16;p13)[20] | 46,XX,t(4;12) (p16;p13)[2] 46,XX[18] | 46,XX,t(4;12) (p16;p13), inc[1]46,XX[39] | 46,XX,t(4;12)(p16;p13) [2]46,XX, t(3;8)(q27;q24), t(4;12)(p16;p13)[1] | 46,XX, t(2;2)(p21;p25), t(3;8)(q27;q24), t(4;12)(p16;p13) add(7)(q22) [20] |
| Chemotherapy | THP-COP(THP+CPA+VCR+PSL) | THP-COP (THP+CPA+VCR+PSL) | IDA+Ara-C MIT+Ara-C | DNR+Ara-C c+PSL ACR+Ara-C c+PSL | Ara-C+VP-16+PSL,VCR,VDS | Ara-C+VP-16+PSL,VCR,VDS | Palliative therapy |
| RT-PCR for TEL-FGFR3 | +, BM | +, BM | +, BM; +, PB | ND | ND | ND | +, PB |
NHL indicates non-Hodgkin lymphoma; CR, complete remission; ND, not done; NR, no response; THP, pirarubicin; COP, cyclophosphamide, Oncovin (vincristine sulfate), prednisone; CPA, cyclophosphamide; VCR, vincristine; PSL, prednisolone; IDA, idarubicin; Ara-C, cytarabine; MIT, mitoxantrone; DNR, daunorubicin; ACR, aclarubicin; VP-16, etoposide; VDS, vindesine.
The karyotypes were described according to the International System for Human Cytogenetic Nomenclature, ISCN23